Three Key Laboratory Tests Concerning for Polycythemia
The three most concerning laboratory findings for polycythemia are: (1) elevated hemoglobin/hematocrit above sex-specific thresholds, (2) low or inappropriately normal serum erythropoietin (EPO) level, and (3) presence of JAK2 mutation (particularly JAK2 V617F). These three tests form the diagnostic cornerstone for distinguishing primary polycythemia vera from secondary causes 1, 2, 1.
1. Elevated Hemoglobin/Hematocrit (First Major Criterion)
Hemoglobin >18.5 g/dL in men or >16.5 g/dL in women, or hematocrit >55% in men or >49.5% in women represents the primary laboratory threshold that should trigger diagnostic evaluation 1, 3.
- Alternatively, a sustained increase in hemoglobin ≥2 g/dL above individual baseline, even if within normal reference range, warrants investigation when accompanied by other concerning features 1.
- Hematocrit values >60% in men or >55% in women virtually always indicate true polycythemia rather than relative polycythemia 2, 4.
- These thresholds represent the 95th percentile adjusted for sex and race, and must be confirmed with repeat measurements rather than relying on a single value 2.
Critical pitfall: Do not assume normal hemoglobin/hematocrit excludes polycythemia vera if the patient has iron deficiency or recent bleeding, as these can mask an elevated red cell mass 2, 5.
2. Low Serum Erythropoietin Level (Minor Criterion)
Serum EPO below the reference range for normal is highly specific (>90%) for polycythemia vera, distinguishing it from secondary causes where EPO is typically elevated or normal 2.
- Low EPO reflects autonomous, JAK2-driven erythropoiesis that suppresses normal EPO feedback mechanisms 6.
- However, sensitivity is only 64-70%, meaning normal EPO levels do not exclude polycythemia vera and still require JAK2 testing 2, 6.
- EPO is unlikely to be elevated in polycythemia vera; if EPO is high, systematically evaluate for secondary causes including hypoxia-driven processes (smoking, sleep apnea, chronic lung disease) or hypoxia-independent causes (renal cell carcinoma, hepatocellular carcinoma, other EPO-producing tumors) 2, 6.
Critical pitfall: In chronic hypoxic states causing secondary polycythemia, EPO may normalize after hemoglobin stabilizes at a compensatory higher level, potentially mimicking polycythemia vera 2, 6. Always correlate with clinical context and JAK2 status.
3. JAK2 Mutation (Second Major Criterion)
Presence of JAK2 V617F or other functionally similar JAK2 mutation captures >97% of polycythemia vera cases and has become the defining molecular marker 1, 3.
- The revised WHO criteria require both major criteria (elevated hemoglobin/hematocrit AND JAK2 mutation) plus at least one minor criterion for diagnosis 1.
- Alternative diagnostic pathway: first major criterion (elevated hemoglobin/hematocrit) plus two minor criteria can diagnose polycythemia vera in JAK2-negative cases, though these are rare 1.
- JAK2 testing should be ordered immediately alongside EPO levels when polycythemia is suspected 6, 7.
Critical pitfall: A positive JAK2 mutation does not automatically confirm polycythemia vera—you still need elevated hemoglobin/hematocrit and at least one minor criterion to meet diagnostic requirements and avoid false-positive molecular results 1.
Supporting Laboratory Findings
While not among the three most critical tests, these additional findings strengthen the diagnosis:
- Thrombocytosis (platelets >400 × 10⁹/L) occurs in 53% of polycythemia vera patients 1, 3.
- Leukocytosis (WBC >12 × 10⁹/L) occurs in 49% of cases 1, 3.
- Bone marrow biopsy showing panmyelosis with prominent erythroid and megakaryocytic proliferation serves as a minor criterion when diagnosis is equivocal 1.
Practical Diagnostic Algorithm
Step 1: Confirm elevated hemoglobin/hematocrit with repeat measurements 2, 7.
Step 2: Order serum EPO level and JAK2 mutation testing simultaneously 2, 6.
Step 3: If EPO is low or normal AND JAK2 is positive, proceed to bone marrow biopsy to confirm one minor criterion and establish polycythemia vera diagnosis 1, 2, 1.
Step 4: If EPO is elevated, systematically exclude secondary causes: smoking history, sleep study for apnea, chest imaging for chronic lung disease, abdominal imaging for renal/hepatic tumors, medication review for testosterone or EPO use 2, 6.
Step 5: If JAK2 is negative but clinical suspicion remains high (splenomegaly, aquagenic pruritus, unusual thrombosis), bone marrow examination becomes mandatory to identify the rare JAK2-negative polycythemia vera cases 1, 2, 1, 2.